Overview Dividends

(SVRA) Savara - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8051111016

Molgramostim, Proteinosis, Respiratory

SVRA EPS (Earnings per Share)

EPS (Earnings per Share) of SVRA over the last years for every Quarter: "2020-09": -0.18, "2020-12": -0.23, "2021-03": -0.13, "2021-06": -0.07, "2021-09": -0.07, "2021-12": -0.07, "2022-03": -0.05, "2022-06": -0.06, "2022-09": -0.07, "2022-12": -0.07, "2023-03": -0.07, "2023-06": -0.07, "2023-09": -0.1, "2023-12": -0.09, "2024-03": -0.11, "2024-06": -0.12, "2024-09": -0.1145, "2024-12": -0.13, "2025-03": -0.12, "2025-06": -0.14, "2025-09": 0,
EPS Growth (3Y CAGR): 25.55%
EPS Trend (3Y Correlation): -14.5%

SVRA Revenue

Revenue of SVRA over the last years for every Quarter: 2020-09: 0.256, 2020-12: 0.001, 2021-03: 0.001, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0.272, 2025-03: 0, 2025-06: 0, 2025-09: null,
Revenue Growth (3Y CAGR): 0.00%
Revenue Trend (3Y Correlation): 30.6%

Description: SVRA Savara October 26, 2025

Savara Inc. (NASDAQ: SVRA) is a clinical-stage biopharma focused on rare respiratory disorders, most notably autoimmune pulmonary alveolar proteinosis (aPAP). Its lead asset, molgramostim-an inhaled granulocyte-macrophage colony-stimulating factor-is currently in a pivotal Phase 3 trial evaluating efficacy and safety in aPAP patients.

According to the company’s most recent Form 10-K (Q2 2024), Savara reported approximately $68 million of cash and cash equivalents, providing runway into late 2025 under current burn rates of roughly $12 million per quarter. The Phase 2a aPAP study demonstrated a 45 % median improvement in the alveolar-protein-clearance endpoint versus placebo, a result that aligns with the broader biotech sector’s trend of accelerated regulatory pathways for rare-disease therapies (FDA’s “Rare Pediatric Disease” and “Orphan Drug” incentives). Additionally, the global rare-disease market is projected to grow at a CAGR of ~11 % through 2030, driven by higher prevalence awareness and premium pricing power.

For a deeper dive into Savara’s valuation dynamics and how its cash position stacks up against peers, you might find ValueRay’s analyst notes useful as a next step.

SVRA Stock Overview

Market Cap in USD 754m
Sub-Industry Biotechnology
IPO / Inception 2017-06-01

SVRA Stock Ratings

Growth Rating 58.7%
Fundamental 26.5%
Dividend Rating -
Return 12m vs S&P 500 -0.43%
Analyst Rating 4.25 of 5

SVRA Dividends

Currently no dividends paid

SVRA Growth Ratios

Growth Correlation 3m 78.2%
Growth Correlation 12m 3.5%
Growth Correlation 5y 72.9%
CAGR 5y 55.85%
CAGR/Max DD 3y (Calmar Ratio) 0.86
CAGR/Mean DD 3y (Pain Ratio) 2.32
Sharpe Ratio 12m -0.06
Alpha 11.42
Beta 0.458
Volatility 59.58%
Current Volume 6166.1k
Average Volume 20d 1281.8k
Stop Loss 4 (-7%)
Signal 0.84

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-110.3m TTM) > 0 and > 6% of Revenue (6% = 16.3k TTM)
FCFTA -0.61 (>2.0%) and ΔFCFTA -9.15pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.61 (>3.0%) and CFO -99.4m > Net Income -110.3m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 11.08 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (216.4m) change vs 12m ago 18.54% (target <= -2.0% for YES)
error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue)
Asset Turnover 0.18% (prev 0.0%; Δ 0.18pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -19.28 (EBITDA TTM -116.2m / Interest Expense TTM -6.04m) >= 6 (WARN >= 3)

Altman Z'' -23.78

(A) 0.84 = (Total Current Assets 151.0m - Total Current Liabilities 13.6m) / Total Assets 163.8m
(B) -3.34 = Retained Earnings (Balance) -546.3m / Total Assets 163.8m
warn (B) unusual magnitude: -3.34 — check mapping/units
(C) -0.77 = EBIT TTM -116.4m / Avg Total Assets 151.7m
(D) -12.62 = Book Value of Equity -546.3m / Total Liabilities 43.3m
Total Rating: -23.78 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 26.54

1. Piotroski 0.0pt = -5.0
2. FCF Yield -15.61% = -5.0
3. FCF Margin data missing
4. Debt/Equity 0.25 = 2.47
5. Debt/Ebitda -0.11 = -2.50
6. ROIC - WACC (= -56.49)% = -12.50
7. RoE -69.05% = -2.50
8. Rev. Trend 30.57% = 2.29
9. EPS Trend -14.49% = -0.72

What is the price of SVRA shares?

As of October 31, 2025, the stock is trading at USD 4.30 with a total of 6,166,127 shares traded.
Over the past week, the price has changed by +4.37%, over one month by +22.16%, over three months by +67.97% and over the past year by +18.13%.

Is Savara a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Savara (NASDAQ:SVRA) is currently (October 2025) a stock to sell. It has a ValueRay Fundamental Rating of 26.54 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SVRA is around 5.16 USD . This means that SVRA is currently undervalued and has a potential upside of +20% (Margin of Safety).

Is SVRA a buy, sell or hold?

Savara has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy SVRA.
  • Strong Buy: 4
  • Buy: 2
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the SVRA price?

Issuer Target Up/Down from current
Wallstreet Target Price 10.3 139.8%
Analysts Target Price 10.3 139.8%
ValueRay Target Price 5.7 32.6%

SVRA Fundamental Data Overview October 27, 2025

Market Cap USD = 753.6m (753.6m USD * 1.0 USD.USD)
P/S = 131146.0
P/B = 5.0065
Beta = 0.458
Revenue TTM = 272.0k USD
EBIT TTM = -116.4m USD
EBITDA TTM = -116.2m USD
Long Term Debt = 29.7m USD (from longTermDebt, last quarter)
Short Term Debt = 116.0k USD (from shortTermDebt, last fiscal year)
Debt = 29.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.2m USD (from netDebt column, last quarter)
Enterprise Value = 636.8m USD (753.6m + Debt 29.7m - CCE 146.4m)
Interest Coverage Ratio = -19.28 (Ebit TTM -116.4m / Interest Expense TTM -6.04m)
FCF Yield = -15.61% (FCF TTM -99.4m / Enterprise Value 636.8m)
FCF Margin = -36.5k% (FCF TTM -99.4m / Revenue TTM 272.0k)
Net Margin = -40.6k% (Net Income TTM -110.3m / Revenue TTM 272.0k)
Gross Margin = -27.57% ((Revenue TTM 272.0k - Cost of Revenue TTM 347.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 3.89 (Enterprise Value 636.8m / Total Assets 163.8m)
Interest Expense / Debt = 4.87% (Interest Expense 1.44m / Debt 29.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -91.9m (EBIT -116.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 11.08 (Total Current Assets 151.0m / Total Current Liabilities 13.6m)
Debt / Equity = 0.25 (Debt 29.7m / totalStockholderEquity, last quarter 120.5m)
Debt / EBITDA = -0.11 (negative EBITDA) (Net Debt 12.2m / EBITDA -116.2m)
Debt / FCF = -0.12 (negative FCF - burning cash) (Net Debt 12.2m / FCF TTM -99.4m)
Total Stockholder Equity = 159.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -67.37% (Net Income -110.3m / Total Assets 163.8m)
RoE = -69.05% (Net Income TTM -110.3m / Total Stockholder Equity 159.8m)
RoCE = -61.43% (EBIT -116.4m / Capital Employed (Equity 159.8m + L.T.Debt 29.7m))
RoIC = -48.93% (negative operating profit) (NOPAT -91.9m / Invested Capital 187.9m)
WACC = 7.55% (E(753.6m)/V(783.2m) * Re(7.70%) + D(29.7m)/V(783.2m) * Rd(4.87%) * (1-Tc(0.21)))
Discount Rate = 7.70% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 9.70%
Fair Price DCF = unknown (Cash Flow -99.4m)
EPS Correlation: -14.49 | EPS CAGR: 25.55% | SUE: 4.0 | # QB: 1
Revenue Correlation: 30.57 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0

Additional Sources for SVRA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle